GEN Exclusives

More »

GEN News Highlights

More »
Feb 22, 2011

Moleculence to Use Pronota's Platforms to Find Biomarkers for Stroke

  • Pronota signed an agreement allowing its MASStermind® platform for protein biomarker discovery and its MASSterclass™ biomarker verification platform to be used by Molecuence. The company will leverage the technologies to discover and validate protein biomarkers in stroke.

    Pronota develops protein biomarker diagnostics using a platform that mines for low-abundance protein biomarkers in blood and other tissues. MASSterclass™ verifies biomarkers identified by MASStermind® without the use of antibody-based assays, according to the company.

    Promota's pipeline consists of four programs focused on diagnostic blood tests for cardiorenal disease, pre-eclampsia, sepsis, and ovarian cancer. Founded in late 2004, Pronota announced the raising of a series B financing round of €7.9 million (about $10.8 million) last year.

    Moleculence, a wholly owned subsidiary of Mitsubishi Chemical, focuses on R&D of advanced biomarkers that can enable diagnosis and prediction of cardiovascular and metabolic diseases. Molecuence works with researchers at Kyushu University Faculty of Medicine and Hisayama Research Institute for Lifestyle Diseases.

     

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?